Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (ad5CMV-p53) in human pancreatic cancer

Cancer Gene Therapy

Volumn 7, Issue 4, 2000, Pages 545-556

  Cascalló, Manel ^b   Calbó, Joaquim ^b   Gelpí, Josef Lluís ^b   Mazo, Adela ^a,b  

^a Dept de Bioquim i Biol Molecular ^*  (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adenovirus; Apoptosis; Chemotherapy; p53; Pancreatic cancer

Indexed keywords

CISPLATIN; GEMCITABINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADENOVIRIDAE; ANIMALIA;

EID: 0034039072     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700150     Document Type: Article

References (45)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin. 1995;45:8-30.
2. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995;31A:882-887.
3. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
4. Culver KW, Blaese RM. Gene therapy for cancer. Trends Genet. 1994;10:174-178.
5. King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem. 1995;8:175-185.
6. Favrot M, Coll JL, Louis N, Negoescu A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther. 1998;5:728-739.
7. Lowe SC, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell. 1993;74:957-967.
8. Hollstein M, Sidranski D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
9. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of the p53 protein in the response to DNA damage. Cancer Res. 1991;51:6304-6311.
11. Lane DP. p53, guardian of the genome. Nature. 1992;358: 15-16.
12. El-Deiry WS, Tokino K, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993; 75:817-825.
13. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701-704.
14. 2/M by p53. Oncogene. 1995;10:109-115.
15. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 1995;92:8493-8497.
16. 2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene. 1995;10:2263-2270.
17. 2 to M transition: implications for gene therapy. Cancer Res. 1997;57:818-823.
18. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
19. Wu S, El-Deiry WS. p53 and chemosensitivity. Nat Med. 1996;2:255-256.
20. Lowe SW, Bodis S, McClatchey A, et al. P53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-810.
21. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996;56:892-898.
22. 2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer. 1998;75:432-438.
23. Wang J, Bucana CD, Roth JA, Zhang WW. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther. 1995;2:9-17.
24. Gómez-Manzano C, Fueyo J, Kyritsis P, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996;56:694-699.
25. 1 arrest and induces apoptosis in human cancer cells. Oncogene. 1997;5:1903-1909.
26. Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56:3047-3054.
27. Liu TJ, El-Naggar K, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995;55:3117-3122.
28. Yang C, Stambrook PJ, Markowitz SD. Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest. Clin Cancer Res. 1996;2:1639-1647.
29. Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 1996;16:3415-3422.
30. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology. 1996;24:1264-1268.
31. Gjerset RA, Turla ST, Sobol RE, et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog. 1995;14:275-285.
32. Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem. 1995;270:1894-1898.
33. Kimura M, Tagawa M, Takenaga K, et al. Inability to induce the alteration of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res. 1997;17:879-884.
34. Lang D, Miknyoczki SJ, Huang L, Ruggeri BA. Stable reintroduction of wild-type p53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Oncogene. 1998;16:1593-1602.
35. Cascalló M, Mercadé E, Lluís F, et al. Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther. 1999;6:428-436.
36. Villanueva A, García C, Paules AB, et al. Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cells Oncogene. 1998;17:1969-1978.
37. Sagawe Y, Yamagishi H, Yamaguchi N, Yamamura Y, Oka T. In vitro chemosensitivity of human pancreatic cancer cell lines. Int J Pancreatol. 1996;20:185-190.
38. Lee JU, Hosotani R, Wada M, et al. Mechanism of apoptosis induced by cisplatin and VP-16 in PANC-1 cells. Anticancer Res. 1997;17:3445-3450.
39. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-1455.
40. Stucky-Marshall L. New agents in gastrointestinal malignancies: Part 2: GEMCITABINE in clinical practice. Cancer Nurs. 1999; 22:290-296.
41. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
42. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
43. Yin C, Knudson CM, Korsmeyer SJ, van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385:637-640.
44. Fujiwara T, Grimm EA, Mukhoadhyay T, Zhang WW, Owe-Schaub B, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54: 2287-2291.
45. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg. 1996;112:1372-1376.